The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples

International Journal of Cancer

Volumn 139, Issue 3, 2016, Pages 691-699

  Ebisch, Renée M F ^a   De Kuyper De Ridder, Gabriëlle M ^a   Bosgraaf, Remko P ^a,b   Massuger, Leon F A G ^a   Inthout, Joanna ^a   Verhoef, Viola M J ^c   Heideman, Daniëlle A M ^c   Snijders, Peter J F ^c   Meijer, Chris J L M ^c   Van Kemenade, Folkert J ^d   Bulten, Johan ^a   Siebers, Albert G ^a   Bekkers, Ruud L M ^a   Melchers, Willem J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JEROEN BOSCH HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

cervical carcinoma; cervical intraepithelial neoplasia; genotyping; human papillomavirus; screening; triage

Indexed keywords

ADULT; ARTICLE; CANCER SCREENING; CANCER STAGING; CERVICOVAGINAL SELF-SAMPLING DEVICE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; LAVAGE; MAJOR CLINICAL STUDY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; POST HOC ANALYSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; EMERGENCY HEALTH SERVICE; GENETICS; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; GENOTYPE; HUMANS; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84963628539     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30090     Document Type: Article

References (31)

1. Walboomers JM, Jacobs MV, Manos MM, et al., Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
2. Cuzick J, Clavel C, Petry KU, et al., Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Can 2006; 119: 1095-101.
3. Ebisch RMF, Rovers MM, Bosgraaf RP, et al., Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis. Bjog 2016; 123: 59-66.
4. Bosgraaf RP, de Jager WC, Servaes P, et al., Qualitative insights into the psychological stress before and during colposcopy: a focus group study. J Psychosom Obstet Gynaecol 2013; 34: 150-6.
5. Bekkers RL, van der Donck M, Klaver FM, et al., Variables influencing anxiety of patients with abnormal cervical smears referred for colposcopy. J Psychosom Obstet Gynaecol 2002; 23: 257-61.
6. Arbyn M, Kyrgiou M, Simoens C, et al., Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008; 337: a1284.
7. Rijkaart DC, Berkhof J, van Kemenade FJ, et al., Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Can 2012; 130: 602-10.
8. Dijkstra MG, van Niekerk D, Rijkaart DC, et al., Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiol Biomarkers Prev 2014; 23: 55-63.
9. Castle PE, Stoler MH, Wright TC, et al., Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. The Lancet Oncol 2011; 12: 880-90.
10. Cox JT, Castle PE, Behrens CM, et al., Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 2013; 208: e1-184 e11.
11. Bosgraaf RP, Verhoef VM, Massuger LFAG, et al., Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening. Int J Can 2015; 136: 646-55.
12. Bulk S, Van Kemenade FJ, Rozendaal L, et al., The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 2004; 57: 388-93.
13. Hanselaar AG., Criteria for organized cervical screening programs. Special emphasis on The Netherlands program. Acta Cytol 2002; 46: 619-29.
14. Bosgraaf RP, Mast PP, Struik-van der Zanden PH, et al., Overtreatment in a see-and-treat approach to cervical intraepithelial lesions. Obstet Gynecol 2013; 121: 1209-16.
15. Casparie M, Tiebosch AT, Burger G, et al., Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007; 29: 19-24.
16. Heideman DA, Hesselink AT, Berkhof J, et al., Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol 2011; 49: 3983-5.
17. Stoler MH, Wright TC, Sharma A, et al., High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol 2011; 135: 468-75.
18. Castle PE, Sideri M, Jeronimo J, et al., Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol 2007; 197: 356 e1-6.
19. Kosinski AS., A weighted generalized score statistic for comparison of predictive values of diagnostic tests. Stat Med 2013; 32: 964-77.
20. R Core Team. A language and environment for statistical computing. Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/. Retrieved January 2015.
21. Stock C, Hielscher T., DTComPair: comparison of binary diagnostic tests in a paired study design. Package version 1.0.1. Available at: http://CRAN.R-project.org/package=DTComPair.
22. Heinonen A, Gissler M, Riska A, et al., Loop electrosurgical excision procedure and the risk for preterm delivery. Obstet Gynecol 2013; 121: 1063-8.
23. Khan MJ, Castle PE, Lorincz AT, et al., The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. JNCI 2005; 97: 1072-9.
24. Kjaer SK, Frederiksen K, Munk C, et al., Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. JNCI 2010; 102: 1478-88.
25. Uijterwaal MH, Polman NJ, van Kemenade FJ, et al., Five-year cervical (Pre)cancer risk of women screened by HPV and cytology testing. Can Prev Res 2015; 8: 502-9.
26. Bulkmans NW, Berkhof J, Rozendaal L, et al., Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
27. Moriarty AT, Nayar R, Arnold T, et al., The Tahoe Study: bias in the interpretation of Papanicolaou test results when human papillomavirus status is known. Arch Pathol Lab Med 2014; 138: 1182-5.
28. Stoler MH, Schiffman M., Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285: 1500-5.
29. Bosgraaf RP, Siebers AG, De Hullu JA, et al., The current position and the future perspectives of cervical cancer screening. Exp Rev Anticancer Ther 2014; 14: 75-92.
30. Verhoef VM, Bosgraaf RP, van Kemenade FJ, et al., Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol 2014; 15: 315-22.
31. Steenbergen RD, Snijders PJ, Heideman DA, et al., Clinical implications of (epi)genetic changes in HPV-induced cervical precancerous lesions. Nat Rev Cancer 2014; 14: 395-405.